|  |
| --- |
|  **Supplementary table 1: Completed phase 3 clinical trials on immunotherapy for patient with advanced or metastatic renal cell carcinoma** |
| **Line of therapy** | **Agent** | **Trial name**  | **Inclusion criteria** | **Number of patients** | **Objective response rate (%)**  | **Complete response and partial response (%)** | **Median progression free survival (months)** | **Adverse events (%)** |
| Not first | **Nivolumab vs Everolimus** | CheckMate 025 | Patients with advanced or metastatic ccRCC histologically confirmed | 821 | 25 vs 5 | 1/24vs1/5 | 5 vs 4 | Grade 3-4=19 vs 37 |
| First | **Nivolumab****+****Ipilimubab****vs****Sunitinib** | CheckMate 214 | Patients with advanced or metastatic ccRCC histologically confirmed | 1096 | Intermediate/poor risk42 vs 27 | 9/32vs1/25 | Intermediate/poor risk12 vs 8 | Grade 3-446 vs 63 |
| **Atezolizumab + Bevacizumab vs Sunitinib** | IMmotion151 | Unresectable locally advanced or metastatic ccRCC with or without sarcomatoid feature | 915 | Intent to treat37 vs 33 Intent to treat with PD-L1 > 1%43 vs 35 | - | Intent to treat11 vs 8Intent to treat with PD-L1>1%11 vs 8 | Grade 2-440 vs 54 |